Randomized trial: In patients with colorectal peritoneal metastases, adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery does not improve survival and causes more frequent late complications
26 Jan, 2021 | 00:34h | UTCCytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
New online: PRODIGE 7 – #Cytoreductive #surgery plus hyperthermic intraperitoneal chemotherapy #HIPEC versus cytoreductive surgery alone for colorectal peritoneal metastases https://t.co/NuGwVmAnbt pic.twitter.com/NLk1DwwIXM
— The Lancet Oncology (@TheLancetOncol) January 19, 2021